V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10430766 | 10057337 | 1.86 | 0 | Palliative (P) | 2017-06-14 | 2017-06-14 | PCV | 01 | N | AML18 TRIAL | 101304162 |
| 10430797 | 10057338 | 1.71 | 81.3 | Palliative (P) | 2019-10-26 | 2019-10-26 | Fulvestrant + Ribociclib | 02 | N | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 100572645 |
| 10430927 | 10057340 | 1.66 | 61.9 | null | 2021-04-01 | 2021-07-07 | PETREA TRIAL | 02 | null | GDP | 101607791 |
| 10430929 | 10057341 | 1.58 | 53 | Adjuvant (A) | 2021-03-19 | 2021-04-06 | Folfirinox/ Folfoxiri | 02 | N | DOCETAXEL + TRASTUZUMAB | 100240285 |
| 10431031 | 10057343 | 1.65 | 102.4 | null | 2018-11-04 | 2018-11-04 | ATEZOLIZUMAB + CARBOPLATIN + ETOPOSIDE | 02 | null | CISPLATIN + ETOPOSIDE + PACLITAXEL | 100018136 |
| 10431072 | 10057345 | 1.55 | 67.2 | Neo-adjuvant (N) | 2021-01-12 | 2021-01-20 | EVEROLIMUS + EXEMESTANE | 02 | N | ERIBULIN | 100546999 |
| 10431192 | 10057347 | 1.83 | 88.3 | null | 2019-07-15 | 2019-08-05 | Irinotecan | 02 | null | FLAIR TRIAL | 101121873 |
| 10431383 | 10057349 | 0 | 64.9 | Palliative (P) | 2018-02-24 | 2018-09-22 | MPV (cycle 1-4) | 02 | N | CLADRIBINE | 100178805 |
| 10431396 | 10057350 | 0 | 59 | Curative (C) | 2019-10-01 | 2019-10-01 | R GDP | N | N | NOT MATCHED | 101036371 |
| 10431408 | 10057351 | 1.67 | 79.9 | Curative (C) | 2021-04-27 | 2021-04-27 | PLATFORM Trial | 02 | N | RIALTO TRIAL | 100352002 |
| 10431514 | 10057352 | 1.69 | 75.1 | null | 2020-01-18 | 2020-01-25 | ETOPOSIDE + MELPHALAN | 02 | null | GEMCITABINE + OXALIPLATIN | 100349527 |
| 10431550 | 10057353 | 1.84 | 70.6 | null | 2019-07-26 | 2019-08-10 | Everolimus 10mg | null | null | OLAPARIB | 101823083 |
| 10431586 | 10057354 | 1.72 | 82 | null | 2017-07-29 | 2017-12-15 | Carboplatin + Pembrolizumab + Pemetrexed | null | null | CARBOPLATIN + DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100908116 |
| 10431592 | 10057355 | 1.67 | 76.6 | Adjuvant (A) | 2018-10-30 | 2018-11-07 | BLEOMYCIN | 02 | N | BRENTUXIMAB | 101670427 |
| 10431812 | 10057356 | 1.61 | 65.05 | null | 2018-06-23 | 2018-06-27 | EC | 02 | null | BLEOMYCIN | 100921645 |
| 10431884 | 10057358 | null | null | null | 2016-10-21 | 2016-10-21 | CISPLATIN + FLUOROURACIL | 02 | null | STAMPEDE TRIAL | 100540443 |
| 10432088 | 10057359 | null | 82.2 | null | 2018-03-30 | 2019-01-14 | Lomustine | 02 | null | ABEMACICLIB + FULVESTRANT | 101810634 |
| 10432265 | 10057360 | 1.68 | 49.4 | null | 2021-02-04 | 2021-02-16 | Cytarabine Low Dose | null | null | CYCLOPHOSPHAMIDE + ETOPOSIDE + LOMUSTINE | 101175110 |
| 10432405 | 10057361 | null | 72.25 | null | 2021-09-20 | 2021-09-20 | Letrozole + Palbociclib | 02 | null | BEVACIZUMAB + OLAPARIB | 100937159 |
| 10432618 | 10057363 | 1.66 | 83.25 | Neo-adjuvant (N) | 2020-03-11 | 2020-03-11 | ALL UKALL60+ TRIAL | 02 | N | VISMODEGIB | 101261049 |
| 10432730 | 10057367 | 1.59 | 49.05 | null | 2019-06-25 | 2019-07-09 | LENALIDOMIDE + RITUXIMAB | 02 | null | BEVACIZUMAB | 100429081 |
| 10432767 | 10057368 | 1.6 | 54.5 | null | null | 2018-03-25 | Folfirinox/ Folfoxiri | 02 | null | SUNITINIB | 100276369 |
| 10432816 | 10057369 | 1.63 | 0 | null | 2019-11-01 | 2020-10-02 | CARBOPLATIN + GEMCITABINE | 02 | null | BEVACIZUMAB | 101311167 |
| 10433098 | 10057376 | null | null | Palliative (P) | 2015-02-19 | 2018-06-17 | Everolimus 10mg | 2 | N | DOXORUBICIN + OLARATUMAB | 101550255 |
| 10433116 | 10057377 | 1.63 | 107.95 | null | 2018-02-23 | 2018-04-02 | Pemetrexed | 02 | null | CISPLATIN + ETOPOSIDE | 101635231 |
| 10433120 | 10057378 | 1.65 | null | Palliative (P) | 2015-12-14 | 2016-07-05 | Binimetinib + Encorafenib | 02 | N | BENDAMUSTINE | 101538191 |
| 10433134 | 10057379 | 1.66 | null | null | 2018-08-23 | 2018-08-29 | LENALIDOMIDE + RITUXIMAB | 02 | null | FULVESTRANT + PALBOCICLIB | 100634860 |
| 10433229 | 10057383 | null | 72.2 | Adjuvant (A) | 2018-04-11 | 2018-04-26 | ABEMACICLIB + FULVESTRANT | 02 | N | GEMCITABINE + NAB-PACLITAXEL | 100198833 |
| 10433242 | 10057384 | 0 | 76 | Disease modification (D) | null | 2019-06-12 | Durvalumab | 02 | N | CARFILZOMIB | 101633082 |
| 10433266 | 10057385 | 1.52 | 0 | Curative (C) | 2021-06-20 | 2021-08-01 | PEMBROLIZUMAB + PEMETREXED | 02 | N | ERIBULIN | 101378340 |
| 10433349 | 10057387 | 1.72 | 97.8 | null | null | 2019-02-19 | CYCLOPHOSPHAMIDE + THALIDOMIDE | null | null | CYTARABINE + ETOPOSIDE + LOMUSTINE + MELPHALAN | 100573943 |
| 10433380 | 10057388 | 1.85 | 72.3 | null | 2019-12-10 | 2019-12-22 | BEAM | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101727333 |
| 10433765 | 10057390 | 1.58 | 57.5 | null | 2022-05-06 | 2022-05-27 | EC | 02 | null | BENDAMUSTINE | 101096280 |
| 10433785 | 10057391 | 1.8 | 88.1 | Palliative (P) | null | 2018-02-17 | ANAGRELIDE | 02 | N | TRIAL | 101088481 |
| 10433902 | 10057393 | 0 | 95 | null | 2022-02-14 | 2022-02-14 | EOX | 02 | null | LIPOSOMAL DOXORUBICIN | 101792097 |
| 10434009 | 10057395 | 1.7 | 76.8 | Curative (C) | 2017-02-17 | 2017-02-17 | FEC 60 or 75 | 02 | N | THALIDOMIDE | 101751455 |
| 10434010 | 10057396 | 1.66 | 105.9 | Palliative (P) | 2019-06-04 | 2019-06-10 | VISMODEGIB | 02 | N | CYCLOPHOSPHAMIDE + ETOPOSIDE + LOMUSTINE | 101628523 |
| 10434091 | 10057397 | 1.71 | 69.1 | null | 2020-01-21 | 2020-01-21 | Cyclophosphamide + Docetaxel | 02 | null | BENDAMUSTINE + OBINUTUZUMAB | 100936114 |
| 10434144 | 10057398 | null | null | Neo-adjuvant (N) | null | 2019-03-28 | IDELALISIB + RITUXIMAB | 02 | N | CARBOPLATIN + CETUXIMAB + FU | 100083176 |
| 10434359 | 10057399 | 1.6 | 73 | null | 2020-01-27 | 2021-09-23 | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 02 | null | TRAMETINIB | 100491118 |
| 10434471 | 10057401 | 1.65 | 66 | Palliative (P) | 2020-07-31 | 2020-08-05 | BOSUTINIB | 02 | N | EPIRUBICIN | 101375258 |
| 10434715 | 10057403 | 1.7 | 81.6 | Palliative (P) | 2018-05-04 | 2018-10-11 | OSIMERTINIB | 02 | N | CARBOPLATIN + DOCETAXEL | 101251087 |
| 10434732 | 10057404 | 1.73 | 75 | 03 | 2017-12-28 | 2018-01-10 | CYTARABINE | 02 | N | SORAFENIB | 101778289 |
| 10434938 | 10057406 | 1.72 | 57.5 | Adjuvant (A) | 2019-07-10 | 2019-07-31 | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 02 | N | CHOP | 100844368 |
| 10435010 | 10057408 | 1.53 | 72.9 | null | 2021-10-21 | 2021-10-29 | DA 3+8 | N | null | BENDAMUSTINE + BRENTUXIMAB | 100332515 |
| 10435119 | 10057410 | null | null | Palliative (P) | 2019-01-24 | 2019-10-16 | CISPLATIN + FLUOROURACIL | 01 | N | AML17 TRIAL | 101095777 |
| 10435233 | 10057411 | 1.8 | 101 | Palliative (P) | 2017-04-04 | 2017-04-10 | null | 02 | N | CYCLOPHOSPHAMIDE HIGH DOSE | 101597282 |
| 10435479 | 10057413 | 1.7 | 58.7 | null | 2019-12-19 | 2019-12-27 | null | 02 | null | DOCETAXEL + FLUOROURACIL + OXALIPLATIN | 101077852 |
| 10435670 | 10057415 | 1.8 | 83.1 | Palliative (P) | 2019-09-26 | 2019-10-08 | Pemetrexed | 02 | N | CISPLATIN + RT | 101299719 |
| 10435680 | 10057416 | 1.68 | 101.6 | 03 | 2019-01-29 | 2019-09-11 | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 02 | N | CHOP R | 100433817 |